1
|
Gadomski S, Fielding C, García-García A, Korn C, Kapeni C, Ashraf S, Villadiego J, Toro RD, Domingues O, Skepper JN, Michel T, Zimmer J, Sendtner R, Dillon S, Poole KES, Holdsworth G, Sendtner M, Toledo-Aral JJ, De Bari C, McCaskie AW, Robey PG, Méndez-Ferrer S. A cholinergic neuroskeletal interface promotes bone formation during postnatal growth and exercise. Cell Stem Cell 2022; 29:528-544.e9. [PMID: 35276096 PMCID: PMC9033279 DOI: 10.1016/j.stem.2022.02.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Revised: 12/02/2021] [Accepted: 02/10/2022] [Indexed: 11/30/2022]
Abstract
The autonomic nervous system is a master regulator of homeostatic processes and stress responses. Sympathetic noradrenergic nerve fibers decrease bone mass, but the role of cholinergic signaling in bone has remained largely unknown. Here, we describe that early postnatally, a subset of sympathetic nerve fibers undergoes an interleukin-6 (IL-6)-induced cholinergic switch upon contacting the bone. A neurotrophic dependency mediated through GDNF-family receptor-α2 (GFRα2) and its ligand, neurturin (NRTN), is established between sympathetic cholinergic fibers and bone-embedded osteocytes, which require cholinergic innervation for their survival and connectivity. Bone-lining osteoprogenitors amplify and propagate cholinergic signals in the bone marrow (BM). Moderate exercise augments trabecular bone partly through an IL-6-dependent expansion of sympathetic cholinergic nerve fibers. Consequently, loss of cholinergic skeletal innervation reduces osteocyte survival and function, causing osteopenia and impaired skeletal adaptation to moderate exercise. These results uncover a cholinergic neuro-osteocyte interface that regulates skeletogenesis and skeletal turnover through bone-anabolic effects.
Collapse
Affiliation(s)
- Stephen Gadomski
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK; Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA; NIH Oxford-Cambridge Scholars Program in Partnership with Medical University of South Carolina, Charleston, SC 29425, USA
| | - Claire Fielding
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Andrés García-García
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Claudia Korn
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Chrysa Kapeni
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK
| | - Sadaf Ashraf
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
| | - Javier Villadiego
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, (CIBERNED), Madrid 28029, Spain
| | - Raquel Del Toro
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain
| | - Olivia Domingues
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Jeremy N Skepper
- Department of Physiology, Development, and Neuroscience, Cambridge Advanced Imaging Centre, University of Cambridge, Cambridge CB2 3DY, UK
| | - Tatiana Michel
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Jacques Zimmer
- Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur Alzette, Luxembourg
| | - Regine Sendtner
- Institute of Clinical Neurobiology, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany
| | - Scott Dillon
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK
| | - Kenneth E S Poole
- Cambridge NIHR Biomedical Research Centre, Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
| | | | - Michael Sendtner
- Institute of Clinical Neurobiology, University Hospital of Wuerzburg, 97080 Wuerzburg, Germany
| | - Juan J Toledo-Aral
- Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, (CIBERNED), Madrid 28029, Spain
| | - Cosimo De Bari
- Arthritis and Regenerative Medicine Laboratory, Aberdeen Centre for Arthritis and Musculoskeletal Health, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK
| | - Andrew W McCaskie
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Surgery, School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Pamela G Robey
- Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
| | - Simón Méndez-Ferrer
- Wellcome-MRC Cambridge Stem Cell Institute, Cambridge CB2 0AW, UK; Department of Hematology, University of Cambridge, Cambridge CB2 0AW, UK; National Health Service Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK; Instituto de Biomedicina de Sevilla-IBiS (Hospitales Universitarios Virgen del Rocío y Macarena/CSIC/Universidad de Sevilla), 41013 Seville, Spain; Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009 Seville, Spain.
| |
Collapse
|
4
|
Kurogouchi F, Nakane T, Furukawa Y, Hirose M, Inada Y, Chiba S. Heterogeneous distribution of beta-adrenoceptors and muscarinic receptors in the sinoatrial node and right atrium of the dog. Clin Exp Pharmacol Physiol 2002; 29:666-72. [PMID: 12099997 DOI: 10.1046/j.1440-1681.2002.03714.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. The pacemaker site is known to shift away from the sinoatrial (SA) node in response to autonomic stimuli. 2. To test whether the shifting of the impulse-initiation site that occurs during autonomic nerve stimulation can be explained by the spatial distributions of beta-adrenoceptor and muscarinic receptors, we obtained densities (B(max)) and dissociation constants (K((d)) for these receptors in three regions along the sulcus terminalis (the SA node itself and regions superior and inferior to it) and a region of the right atrial appendage in the dog. 3. The Bmax values for [(125)I]-iodocyanopindolol binding to beta-adrenoceptors were not different among the four regions. The Bmax value for [(3)H]-quinuclidinyl benzilate binding to muscarinic receptors was significantly higher in the SA node area than in any other region (P < 0.01), although there was no difference among the other three regions. 4. For each receptor, K(d) values were similar among the four regions. 5. These results suggest that spatial variations in the densities of beta-adrenoceptors and muscarinic receptors are not important for shifting the impulse-initiation site and that other factors, such as non-uniform innervation by autonomic nerve fibres, may be mainly responsible for the pacemaker shift induced by autonomic nerve stimulation.
Collapse
Affiliation(s)
- Fumio Kurogouchi
- Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan
| | | | | | | | | | | |
Collapse
|